Core Viewpoint - The AI Fund Agricultural Bank Healthcare Stock (000913) reported a profit of 142 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1565 yuan, and a net asset value growth rate of 10.67% during the reporting period [2] Fund Performance - As of the end of Q2 2025, the fund's scale was 1.441 billion yuan [13] - The fund's unit net value as of July 17 was 1.875 yuan [2] - The fund's one-year cumulative net value growth rate was 38.71%, ranking 24 out of 53 comparable funds [2] - The fund's three-month cumulative net value growth rate was 26.79%, ranking 28 out of 54 comparable funds [2] - The fund's six-month cumulative net value growth rate was 42.95%, ranking 22 out of 54 comparable funds [2] - The fund's three-year cumulative net value growth rate was -9.44%, ranking 24 out of 46 comparable funds [2] Risk Metrics - The fund's three-year Sharpe ratio was -0.143, ranking 33 out of 46 comparable funds [7] - The maximum drawdown over the past three years was 40.52%, ranking 23 out of 46 comparable funds [8] - The highest single-quarter maximum drawdown occurred in Q1 2021, at 28.61% [8] Investment Strategy - The fund manager defined investment keywords for 2025 as innovation, medical AI, self-control, and state-owned enterprise reform [2] - The average stock position over the past three years was 90.34%, compared to the industry average of 88.16% [11] - The fund reached its highest stock position of 93.72% at the end of Q3 2020 and its lowest of 84.43% at the end of Q3 2024 [11] Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included companies such as Heng Rui Medicine, Zejing Pharmaceutical, and Xinlitai [15]

Core Viewpoint - Nomura expects BeiGene (06160.HK) to achieve its full-year sales and operating profit guidance, raising the target price to HKD 209.92 [1] Financial Performance - The company is projected to report a 33% year-on-year increase in Q2 revenue to USD 1.2 billion, in line with market expectations [1] - Gross margin is anticipated to rise by 0.3% year-on-year to 85.4%, with quarterly net profit expected to be USD 55 million, compared to a loss of USD 120 million in the same quarter last year [1] - For the second half of the year, revenue is expected to increase by 37% year-on-year to USD 2.9 billion, benefiting from the continued global sales growth of BeiGene's products [1] Future Outlook - The company is expected to record a profit of USD 119 million in the second half of the year [1] - Full-year revenue is projected to be between USD 4.9 billion and USD 5.3 billion, indicating a strong likelihood of meeting the annual sales and operating profit guidance [1] - Nomura has maintained a "Buy" rating on BeiGene's H-shares and has adjusted its revenue and profit forecasts for the company upwards by 2.1% and 2%, respectively [1]

Core Insights - The article discusses the phenomenon of "middlemen profiting" in the innovative drug industry, highlighted by the strategic collaboration between BMS and BNT, which involved a $9 billion deal for the drug BNT327, originally licensed from Chinese company Pumice Biotech [1][2] - The rapid increase in valuations and the perceived undervaluation of Chinese biotech firms are emphasized, with examples illustrating how companies like Pumice and Hengrui have faced challenges in capturing the full value of their innovations [1][2][3] Summary by Sections Strategic Collaborations - BMS and BNT's partnership to develop BNT327 is valued at $9 billion, with Pumice Biotech originally licensing the drug for $55 million [1] - Hengrui Pharmaceuticals licensed its asthma drug SHR-1905 to Aiolos Bio for $25 million upfront, which was later sold to GSK for $10 billion, showcasing the significant markup in valuations [2] Market Dynamics - The article highlights the immature valuation system for innovative drug companies in China and their limited international operational capabilities, leading to unfavorable deals [2][3] - The quality of clinical data and the lack of unique assets hinder Chinese companies' bargaining power in the global market [3] Evolution of BD Transactions - The evolution of business development (BD) transactions in China is outlined, with three phases: exploration (pre-2014), development (2015-2019), and explosion (2020-present) [4][5] - The surge in BD transactions is attributed to the establishment of numerous innovative drug companies post-2010 and regulatory changes that encouraged innovation [5][6] License-in and License-out Trends - License-in transactions dominated initially, allowing companies to mitigate risks and shorten development timelines, but led to inflated prices and market bubbles [6][7] - License-out transactions have recently surpassed License-in, indicating a shift in strategy as companies seek immediate cash flow amid financial pressures [8] New Business Models - The emergence of the NewCo model allows companies to retain longer-term control over their product pipelines while attracting investment, marking a shift from traditional licensing agreements [13][14] - The NewCo model has gained traction among various biotech firms, enabling them to better manage their assets and secure funding [13][15] Future Outlook - The article concludes that while "cheap sales" of assets may continue, Chinese biotech firms are increasingly integrating into the global ecosystem, necessitating a focus on maximizing value within the international value chain [15][16]

Core Viewpoint - The innovative drug sector is experiencing a significant surge in stock prices, driven by positive news and market momentum, with both A-shares and Hong Kong stocks showing substantial gains in related companies [1][2][3]. Group 1: Market Performance - On July 17, A-shares saw a collective rise, with the Shanghai Composite Index up by 0.37%, the Shenzhen Component up by 1.43%, and the ChiNext Index up by 1.76% [1]. - The innovative drug sector led the market, with nearly 20 related stocks hitting the daily limit or rising over 10%, including Chengdu XianDai, Saily Medical, and Lisheng Pharmaceutical [1][3]. Group 2: Positive News and Developments - A recent report indicated that the innovative drug "Qiruisuo Wei," developed in China for treating respiratory syncytial virus, has been included in the World Health Organization's priority list for children's medications, potentially providing accessible and affordable treatment for children globally [4][5][6]. - The WHO's initiative aims to accelerate the development of urgently needed children's medications, highlighting the critical need for effective treatments for respiratory syncytial virus, which causes millions of infections and significant mortality among young children each year [5]. Group 3: Policy Support - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, including increasing support for R&D, facilitating access to insurance coverage, and enhancing clinical application [8]. - The introduction of a commercial health insurance directory for innovative drugs marks a significant step in expanding the role of commercial insurance in the multi-tiered healthcare system, providing more opportunities for high-priced innovative drugs [9][10]. Group 4: Industry Outlook - Analysts predict that the domestic innovative drug industry may reach a turning point in 2025, shifting from capital-driven growth to profit-driven growth, presenting opportunities for both performance and valuation recovery [11]. - China's share in global innovative drug business development transactions is expected to increase significantly, with a notable rise in the number and value of projects, particularly in areas like ADC and bispecific antibodies [12].

Group 1 - Hong Kong biopharmaceutical stocks experienced an initial surge, with 康方生物 (09926.HK) rising over 8% [1] - 泰格医药 (03347.HK) increased by more than 4% [1] - 百济神州 (06160.HK) and 复宏汉霖 (02696.HK) both saw nearly 4% gains [1] - 金斯瑞生物科技 (01548.HK) rose by over 3% [1]

特此公告。 百济神州有限公司董事会 A股代码：688235 A股简称：百济神州 公告编号：2025-027 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 自愿披露关于公司举行业绩电话会议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 百济神州有限公司（以下简称"公司"）将于美国东部时间 2025 年 8 月 6 日（星期三）发布根据美国公认会计原则及美国证券交易委员 会适用规则编制的截至 2025 年 6 月 30 日止第二季度未经审计财务业绩 并同步发布根据中国企业会计准则编制的 2025 年半年度主要财务数据 公告。 公司管理团队将于美国东部时间 2025 年 8 月 6 日（星期三）上午 8 时（即北京时间 2025 年 8 月 6 日（星期三）晚上 8 时）举行业绩电话 会议。业绩电话会议将进行网络直播，可通过公司网站投资者关系页面 进 入 ， 网 址 为 https://ir.beonemedicines.com 、 https://sseir.beonemedicine ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 相关ETF 百濟神州有限公司（「本公司」）謹此公佈，本公司將於2025年8月6日（星期三） （即 香港聯交所交易時間之後）報告其根據美國公認會計原則及美國證券交易委員會 適用規則編製的截至2025年6月30日止第二季度的未經審核財務業績。本公司董 事會審計委員會將於2025年8月6日（香港時間）審閱及批准2025年第二季度的財 務業績。 財務業績發佈後，本公司將於美國東部時間2025 年8 月6 日（星期三）上午八時正 （即香港時間2025年8月6日（星期三）下午八時正）舉行電話會議。 電話會議將以網路直播方式進行，網絡直播鏈接可從本公司網站的投資者關係頁 面訪問，網址為 https://ir.beonemedicines.com , https://hkexir.beonemedicin ...

Group 1 - The National Medical Products Administration (NMPA) has accepted the marketing application for Baiyue Shenzhou's Talatuzumab injection, which is intended for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have failed at least second-line treatment [1] - Talatuzumab is a first-in-class DLL3/CD3 bispecific antibody that may bring breakthrough advancements in the treatment of SCLC, a type of lung cancer with a high rate of incidence and mortality [1][2] - SCLC accounts for approximately 15% of all lung cancer cases, with about 70% of patients diagnosed at the extensive stage, leading to a median overall survival (mOS) of only 4 to 5 months after initial treatment [1] Group 2 - DLL3 protein is considered a highly attractive therapeutic target in SCLC, with up to 96% of SCLC patients expressing this protein [2] - Talatuzumab utilizes an innovative T-cell engaging (BiTE) structure, which allows for effective targeting of tumor cells and T-cells, potentially making it a novel therapy for SCLC [2] - Interim analysis from a global Phase 3 clinical trial presented at the 2025 American Society of Clinical Oncology annual meeting showed that Talatuzumab treatment resulted in a median overall survival of 13.6 months, significantly extending survival by 5.3 months compared to standard chemotherapy [2]

百濟神州有限公司（「本公司」）謹此公佈，本公司將於2025年8月6日（星期三）（即 香港聯交所交易時間之後）報告其根據美國公認會計原則及美國證券交易委員會 適用規則編製的截至2025年6月30日止第二季度的未經審核財務業績。本公司董 事會審計委員會將於2025年8月6日（香港時間）審閱及批准2025年第二季度的財 務業績。 財務業績發佈後，本公司將於美國東部時間2025年8月6日（星期三）上午八時正 （即香港時間2025年8月6日（星期三）下午八時正）舉行電話會議。 電話會議將以網路直播方式進行，網絡直播鏈接可從本公司網站的投資者關係頁 面訪問，網址為 https://ir.beonemedicines.com , https://hkexir.beonemedicines.com , https://sseir.beonemedicines.com 。為確保及時連接，建議與會者在預定的網絡直 播前至少15分鐘進行註冊。本公司網站將提供業績電話會議網絡直播的存檔回 放。 本公司另將於2025年8月29日或之前公佈其根據香港聯合交易所有限公司證券上 市規則（「香港上市規則」）編製的截至2025年6月30日止六個 ...

A股代码：688235 A股简称：百济神州 公告编号：2025-027 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 自愿披露关于公司举行业绩电话会议的公告 1 2025 年 7 月 17 日 2 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 百济神州有限公司（以下简称"公司"）将于美国东部时间 2025 年 8 月 6 日（星期三）发布根据美国公认会计原则及美国证券交易委员 会适用规则编制的截至 2025 年 6 月 30 日止第二季度未经审计财务业绩 并同步发布根据中国企业会计准则编制的 2025 年半年度主要财务数据 公告。 公司管理团队将于美国东部时间 2025 年 8 月 6 日（星期三）上午 8 时（即北京时间 2025 年 8 月 6 日（星期三）晚上 8 时）举行业绩电话 会议。业绩电话会议将进行网络直播，可通过公司网站投资者关系页面 进 入 ， 网 址 为 https://ir.beonemedicines.com 、 https://sseir.beonemedici ...